Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer.

Pecqueux C, Arslan A, Heller M, Falkenstein M, Kaczorowski A, Tolstov Y, Sültmann H, Grüllich C, Herpel E, Duensing A, Kristiansen G, Hohenfellner M, Navone NM, Duensing S.

Urol Oncol. 2018 Aug;36(8):365.e15-365.e26. doi: 10.1016/j.urolonc.2018.05.020. Epub 2018 Jun 7.

PMID:
29887238
2.

Genomic features of renal cell carcinoma with venous tumor thrombus.

Warsow G, Hübschmann D, Kleinheinz K, Nientiedt C, Heller M, Van Coile L, Tolstov Y, Trennheuser L, Wieczorek K, Pecqueux C, Gasch C, Kuru T, Nyarangi-Dix J, Hatiboglu G, Teber D, Perner S, Stenzinger A, Roth W, Hadaschik B, Pahernik S, Jäger D, Grüllich C, Duensing A, Eils R, Schlesner M, Sültmann H, Hohenfellner M, Duensing S.

Sci Rep. 2018 May 10;8(1):7477. doi: 10.1038/s41598-018-25544-z.

3.

TMPRSS2:ERG gene fusion variants induce TGF-β signaling and epithelial to mesenchymal transition in human prostate cancer cells.

Ratz L, Laible M, Kacprzyk LA, Wittig-Blaich SM, Tolstov Y, Duensing S, Altevogt P, Klauck SM, Sültmann H.

Oncotarget. 2017 Apr 11;8(15):25115-25130. doi: 10.18632/oncotarget.15931.

4.

Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma.

Hatiboglu G, Hohenfellner M, Arslan A, Hadaschik B, Teber D, Radtke JP, Hallscheidt P, Tolstov Y, Roth W, Grüllich C, Huesing J, Duensing S, Pahernik S.

Langenbecks Arch Surg. 2017 Jun;402(4):637-644. doi: 10.1007/s00423-016-1543-8. Epub 2016 Dec 23.

PMID:
28012035
5.

F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.

Giesel FL, Hadaschik B, Cardinale J, Radtke J, Vinsensia M, Lehnert W, Kesch C, Tolstov Y, Singer S, Grabe N, Duensing S, Schäfer M, Neels OC, Mier W, Haberkorn U, Kopka K, Kratochwil C.

Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):678-688. doi: 10.1007/s00259-016-3573-4. Epub 2016 Nov 26.

6.

Molecular complexity of taxane-induced cytotoxicity in prostate cancer cells.

Mang J, Merkle K, Heller M, Schüler J, Tolstov Y, Li J, Hohenfellner M, Duensing S.

Urol Oncol. 2017 Jan;35(1):32.e9-32.e16. doi: 10.1016/j.urolonc.2016.07.017. Epub 2016 Sep 28.

PMID:
27692847
7.

PARP inhibition in BRCA2-mutated prostate cancer.

Nientiedt C, Tolstov Y, Volckmar AL, Endris V, Bonekamp D, Haberkorn U, Jäger D, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S.

Ann Oncol. 2017 Jan 1;28(1):189-191. doi: 10.1093/annonc/mdw445. No abstract available.

8.

Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression.

Pickl JM, Tichy D, Kuryshev VY, Tolstov Y, Falkenstein M, Schüler J, Reidenbach D, Hotz-Wagenblatt A, Kristiansen G, Roth W, Hadaschik B, Hohenfellner M, Duensing S, Heckmann D, Sültmann H.

Oncotarget. 2016 Sep 13;7(37):59589-59603. doi: 10.18632/oncotarget.10729.

9.

Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity.

Hoefflin R, Lahrmann B, Warsow G, Hübschmann D, Spath C, Walter B, Chen X, Hofer L, Macher-Goeppinger S, Tolstov Y, Korzeniewski N, Duensing A, Grüllich C, Jäger D, Perner S, Schönberg G, Nyarangi-Dix J, Isaac S, Hatiboglu G, Teber D, Hadaschik B, Pahernik S, Roth W, Eils R, Schlesner M, Sültmann H, Hohenfellner M, Grabe N, Duensing S.

Nat Commun. 2016 Jun 13;7:ncomms11845. doi: 10.1038/ncomms11845.

10.

Prognostic Significance and Functional Role of CEP57 in Prostate Cancer.

Mang J, Korzeniewski N, Dietrich D, Sailer V, Tolstov Y, Searcy S, von Hardenberg J, Perner S, Kristiansen G, Marx A, Roth W, Herpel E, Grüllich C, Popeneciu V, Pahernik S, Hadaschik B, Hohenfellner M, Duensing S.

Transl Oncol. 2015 Dec;8(6):487-96. doi: 10.1016/j.tranon.2015.11.004.

11.

Uncoupling of PUMA Expression and Apoptosis Contributes to Functional Heterogeneity in Renal Cell Carcinoma - Prognostic and Translational Implications.

Zhou X, Li J, Marx C, Tolstov Y, Rauch G, Herpel E, Macher-Goeppinger S, Roth W, Grüllich C, Pahernik S, Hohenfellner M, Duensing S.

Transl Oncol. 2015 Dec;8(6):480-6. doi: 10.1016/j.tranon.2015.11.003.

12.

Harnessing the p53-PUMA axis to overcome DNA damage resistance in renal cell carcinoma.

Zhou X, Tolstov Y, Arslan A, Roth W, Grüllich C, Pahernik S, Hohenfellner M, Duensing S.

Neoplasia. 2014 Dec;16(12):1028-35. doi: 10.1016/j.neo.2014.09.012.

13.

Human papillomaviruses in urological malignancies: a critical assessment.

Tolstov Y, Hadaschik B, Pahernik S, Hohenfellner M, Duensing S.

Urol Oncol. 2014 Jan;32(1):46.e19-27. doi: 10.1016/j.urolonc.2013.06.012. Epub 2013 Oct 17. Review.

PMID:
24140249
14.

[Novel preclinical models and biomarkers for prostate cancer].

Korzeniewski N, Tapia-Laliena M, Tolstov Y, Pahernik S, Hadaschik B, Hohenfellner M, Duensing S.

Urologe A. 2013 Sep;52(9):1256-60. doi: 10.1007/s00120-013-3310-6. Review. German.

PMID:
23942741
15.

FGF-2 disrupts mitotic stability in prostate cancer through the intracellular trafficking protein CEP57.

Cuevas R, Korzeniewski N, Tolstov Y, Hohenfellner M, Duensing S.

Cancer Res. 2013 Feb 15;73(4):1400-10. doi: 10.1158/0008-5472.CAN-12-1857. Epub 2012 Dec 12.

16.

Survivin is a therapeutic target in Merkel cell carcinoma.

Arora R, Shuda M, Guastafierro A, Feng H, Toptan T, Tolstov Y, Normolle D, Vollmer LL, Vogt A, Dömling A, Brodsky JL, Chang Y, Moore PS.

Sci Transl Med. 2012 May 9;4(133):133ra56. doi: 10.1126/scitranslmed.3003713.

17.

Asymptomatic primary Merkel cell polyomavirus infection among adults.

Tolstov YL, Knauer A, Chen JG, Kensler TW, Kingsley LA, Moore PS, Chang Y.

Emerg Infect Dis. 2011 Aug;17(8):1371-80. doi: 10.3201/eid1708.110079.

18.

Lack of evidence for direct involvement of Merkel cell polyomavirus (MCV) in chronic lymphocytic leukemia (CLL).

Tolstov YL, Arora R, Scudiere SC, Busam K, Chaudhary PM, Chang Y, Moore PS.

Blood. 2010 Jun 10;115(23):4973-4. doi: 10.1182/blood-2010-03-273177. No abstract available.

19.

Quantitation of human seroresponsiveness to Merkel cell polyomavirus.

Pastrana DV, Tolstov YL, Becker JC, Moore PS, Chang Y, Buck CB.

PLoS Pathog. 2009 Sep;5(9):e1000578. doi: 10.1371/journal.ppat.1000578. Epub 2009 Sep 11.

20.

Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays.

Tolstov YL, Pastrana DV, Feng H, Becker JC, Jenkins FJ, Moschos S, Chang Y, Buck CB, Moore PS.

Int J Cancer. 2009 Sep 15;125(6):1250-6. doi: 10.1002/ijc.24509.

21.

Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors.

Shuda M, Arora R, Kwun HJ, Feng H, Sarid R, Fernández-Figueras MT, Tolstov Y, Gjoerup O, Mansukhani MM, Swerdlow SH, Chaudhary PM, Kirkwood JM, Nalesnik MA, Kant JA, Weiss LM, Moore PS, Chang Y.

Int J Cancer. 2009 Sep 15;125(6):1243-9. doi: 10.1002/ijc.24510.

22.
23.

Survival of human immunodeficiency virus type 1 after rinsing injection syringes with different cleaning solutions.

Abdala N, Crowe M, Tolstov Y, Heimer R.

Subst Use Misuse. 2004 Mar;39(4):581-600.

PMID:
15115214

Supplemental Content

Loading ...
Support Center